Ativan Related Published Studies
Well-designed clinical trials related to Ativan (Lorazepam)
The pharmacokinetic and pharmacodynamic effects of SL65.1498, a GABA-A alpha2,3 selective agonist, in comparison with lorazepam in healthy volunteers. [2009.08]
A randomized, double-blind comparison of lorazepam and chlordiazepoxide in patients with uncomplicated alcohol withdrawal. [2009.05]
Lorazepam versus diazepam-phenytoin combination in the treatment of convulsive status epilepticus in children: A randomized controlled trial. [2009.03.16]
The apolipoprotein E epsilon4 allele and memory performance in HIV-1 seropositive subjects: differences at baseline but not after acute oral lorazepam challenge. [2008.11]
Economic evaluation of propofol and lorazepam for critically ill patients undergoing mechanical ventilation. [2008.03]
Economic evaluation of propofol and lorazepam for critically ill patients undergoing mechanical ventilation. [2008.01.02]
Lorazepam, diphenhydramine, and haloperidol transdermal gel for rescue from chemotherapy-induced nausea/vomiting: results of two pilot trials. [2008.01]
Effect of sedation with dexmedetomidine vs lorazepam on acute brain dysfunction in mechanically ventilated patients: the MENDS randomized controlled trial. [2007.12.12]
Propofol associated with a shorter duration of mechanical ventilation than scheduled intermittent lorazepam: a database analysis using Project IMPACT. [2007.12]
Effects of lorazepam on deductive reasoning. [2007.11]
Lorazepam induces multiple disturbances in selective attention: attentional overload, decrement in target processing efficiency, and shifts in perceptual discrimination and response bias. [2007.09]
Efficacy and Tolerability of a Standardized Herbal Product from Galphimia glauca on Generalized Anxiety Disorder. A Randomized, Double-Blind Clinical Trial Controlled with Lorazepam. [2007.07]
Differential effects of scopolamine and lorazepam on working memory maintenance versus manipulation processes. [2007.06]
Pharmacodynamic and pharmacokinetic effects of TPA023, a GABA(A) alpha(2,3) subtype-selective agonist, compared to lorazepam and placebo in healthy volunteers. [2007.06]
Self-reported sleep, sleepiness, and repeated alcohol withdrawals: a randomized, double blind, controlled comparison of lorazepam vs gabapentin. [2007.02.15]
A validation of the 7.5% CO2 model of GAD using paroxetine and lorazepam in healthy volunteers. [2007.01]
Lorazepam dose-dependently decreases risk-taking related activation in limbic areas. [2006.11]
Neutral and emotional episodic memory: global impairment after lorazepam or scopolamine. [2006.11]
Effects of the amnesic drug lorazepam on complete and partial information retrieval and monitoring accuracy. [2006.11]
GABAergic modulation of diffuse noxious inhibitory controls (DNIC): a test by use of lorazepam. [2006.11]
Efficacy and safety of intranasal lorazepam versus intramuscular paraldehyde for protracted convulsions in children: an open randomised trial. [2006.05.13]
A randomized trial of intermittent lorazepam versus propofol with daily interruption in mechanically ventilated patients. [2006.05]
Dose-dependent retrograde facilitation of verbal memory in healthy elderly after acute oral lorazepam administration. [2006.05]
Efficacy of etifoxine compared to lorazepam monotherapy in the treatment of patients with adjustment disorders with anxiety: a double-blind controlled study in general practice. [2006.04]
Risperidone versus haloperidol, in combination with lorazepam, in the treatment of acute agitation and psychosis: a pilot, randomized, double-blind, placebo-controlled trial. [2006.03]
Some facilitatory effects of lorazepam on dynamic visual binding. [2006.01]
Drugs, memory, and metamemory: a dose-effect study with lorazepam and scopolamine. [2005.11]
Gender differences in response to lorazepam in a human drug discrimination study. [2005.11]
Effects of lorazepam on fear-potentiated startle responses in man. [2005.05]
Effects of lorazepam on short latency afferent inhibition and short latency intracortical inhibition in humans. [2005.04.15]
Anterior limbic alpha-like activity: a low resolution electromagnetic tomography study with lorazepam challenge. [2005.04]
Dose-dependent decrease of activation in bilateral amygdala and insula by lorazepam during emotion processing. [2005.03]
Specific effects of an amnesic drug: effect of lorazepam on study time allocation and on judgment of learning. [2005.01]
Well-designed clinical trials possibly related to Ativan (Lorazepam)
Benzodiazepines for delirium. [2009.10.07]
Plasma tryptophan and tyrosine levels are independent risk factors for delirium in critically ill patients. [2009.07.09]
Rivastigmine for the prevention of postoperative delirium in elderly patients undergoing elective cardiac surgery--a randomized controlled trial. [2009.05]
Differing effects of intracortical circuits on plasticity. [2009.03]
Oral compared with intravenous sedation for first-trimester surgical abortion: a randomized controlled trial. [2009.02]
Remifentanil-propofol analgo-sedation shortens duration of ventilation and length of ICU stay compared to a conventional regimen: a centre randomised, cross-over, open-label study in the Netherlands. [2009.02]
Benzodiazepines for delirium. [2009.01.21]
Clinical evaluation of the Daily Assessment of Symptoms-Anxiety (DAS-A): a new instrument to assess the onset of symptomatic improvement in generalized anxiety disorder. [2009.01]
Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia. [2008.12]
Drug management for acute tonic-clonic convulsions including convulsive status epilepticus in children. [2008.07.16]
A double-blind, randomized, placebo-controlled prophylaxis trial of oxcarbazepine as adjunctive treatment to lithium in the long-term treatment of bipolar I and II disorder. [2008.06]
Effect of pharmacological treatment on temperament and character in panic disorder. [2008.03.15]
Protein kinase C inhibition in the treatment of mania: a double-blind, placebo-controlled trial of tamoxifen. [2008.03]
Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo. [2007.10]
Review: Benzodiazepines in generalized anxiety disorder: heterogeneity of outcomes based on a systematic review and meta-analysis of clinical trials. [2007.09]
The role of sedation tests in identifying sedative drug effects in healthy volunteers and their power to dissociate sedative-related impairments from memory dysfunctions. [2007.08]
A randomized trial comparing local intracervical and combined local and paracervical anesthesia in outpatient hysteroscopy. [2007.03]
Effects of gamma-aminobutyric acid-modulating drugs on working memory and brain function in patients with schizophrenia. [2007.02]
Role of lormetazepam in the treatment of insomnia in the elderly. [2007]
The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. [2006.07]
Sedation and memory: studies with a histamine H-1 receptor antagonist. [2006.07]
Scopolamine induces impairments in the recognition of human facial expressions of anger and disgust. [2006.05]
Sleep maintenance insomnia: strengths and weaknesses of current pharmacologic therapies. [2006.01]
Alcohol withdrawal pharmacotherapy for inpatients with medical comorbidity. [2006]
Profiling the subjective, psychomotor, and physiological effects of tramadol in recreational drug users. [2005.11.01]
Next-day residual effects of hypnotics in DSM-IV primary insomnia: a driving simulator study with simultaneous electroencephalogram monitoring. [2005.10]
Double-blind study of cyamemazine and diazepam in the alcohol withdrawal syndrome. [2005.10]
Morphine, gabapentin, or their combination for neuropathic pain. [2005.03.31]
Double-blind treatment with oral morphine in treatment-resistant obsessive-compulsive disorder. [2005.03]
Psychomotor performance in healthy young adult volunteers receiving lormetazepam and placebo: a single-dose, randomized, double-blind, crossover trial. [2005.01]
Acute and continuation risperidone monotherapy in bipolar mania: a 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidol. [2005.01]
Other research related to Ativan (Lorazepam)
A double-blind trial of gabapentin versus lorazepam in the treatment of alcohol withdrawal. [2009.09]
The detection and quantification of lorazepam and its 3-O-glucuronide in fingerprint deposits by LC-MS/MS. [2009.07]
Development of a cyclodextrin-based nasal delivery system for lorazepam. [2008.08]
Determination of a lorazepam dose threshold for using the osmol gap to monitor for propylene glycol toxicity. [2008.08]
A prospective evaluation of propylene glycol clearance and accumulation during continuous-infusion lorazepam in critically ill patients. [2008.05]
Pharmacokinetic and pharmacodynamic interaction of lorazepam and valproic acid in relation to UGT2B7 genetic polymorphism in healthy subjects. [2008.04]
Effects of lorazepam on visual perceptual abilities. [2008.04]
A randomized double-blind placebo-controlled study of low-dose intravenous Lorazepam to reduce procedural pain during bone marrow aspiration and biopsy. [2008.03]
Catatonic syndrome: importance of detection and treatment with lorazepam. [2008.01]
Pharmacokinetics and clinical efficacy of lorazepam in children with severe malaria and convulsions. [2008.01]
Pilot study of lorazepam and tiagabine effects on sleep, motor learning, and impulsivity in cocaine abstinence. [2008]
Design and evaluation of self-emulsifying drug delivery systems (SEDDS) of nimodipine. [2008]
The Homeopathic Preparation Nervoheel N can Offer an Alternative to Lorazepam Therapy for Mild Nervous Disorders. [2007.10.25]
Premedication with orally administered lorazepam in adults undergoing ERCP: a randomized double-blind study. [2007.09]
Acute kidney injury, hyperosmolality and metabolic acidosis associated with lorazepam. [2007.09]
Pharmacological manipulations of arousal and memory for emotional material: effects of a single dose of methylphenidate or lorazepam. [2007.09]
Pharmacological manipulations of arousal and memory for emotional material: effects of a single dose of methylphenidate or lorazepam. [2007.07.02]
Technological evaluation and equivalence assessment of lorazepam tablets in rabbits. [2007.07]
Idiopathic recurrent catatonia needs maintenance lorazepam: case report and review. [2007.07]
The effects of lorazepam on skin conductance responses to aversive stimuli in healthy subjects. [2007.06]
The CRF1 receptor antagonist R121919 attenuates the neuroendocrine and behavioral effects of precipitated lorazepam withdrawal. [2007.06]
Dissociation between the cognitive process and the phenomenological experience of TOT: effect of the anxiolytic drug lorazepam on TOT states. [2007.06]
Altered benzodiazepine receptor sensitivity in alcoholism: a study with fMRI and acute lorazepam challenge. [2007.04.15]
Symptom-driven lorazepam protocol for treatment of severe alcohol withdrawal delirium in the intensive care unit. [2007.04]
The effects of lorazepam on skin conductance responses to aversive stimuli in healthy subjects. [2007.03.27]
Dissociation between perceptual processing and priming in long-term lorazepam users. [2006.12]
Pain management of first-trimester surgical abortion: effects of selection of local anesthesia with and without lorazepam or intravenous sedation. [2006.11]
Lorazepam concentrations, pharmacokinetics and pharmacodynamics in a cohort of mechanically ventilated ICU patients. [2006.10]
Lorazepam-induced effects on silent period and corticomotor excitability. [2006.09]
Impairment of contrast sensitivity in long-term lorazepam users. [2006.07]
Withdrawal from lorazepam in critically ill children. [2006.06]
Lorazepam and diazepam rapidly relieve catatonic features in major depression. [2006.05]
Population pharmacodynamic modelling of lorazepam- and midazolam-induced sedation upon long-term continuous infusion in critically ill patients. [2006.03]
Quantitative assay of lorazepam and its metabolite glucuronide by reverse-phase liquid chromatography-tandem mass spectrometry in human plasma and urine samples. [2006.02.13]
Osmol gap as a surrogate marker for serum propylene glycol concentrations in patients receiving lorazepam for sedation. [2006.01]
Lorazepam is an independent risk factor for transitioning to delirium in intensive care unit patients. [2006.01]
Lorazepam and MK-801 effects on behavioral and electrographic indices of alcohol withdrawal sensitization. [2005.12.14]
|
